#85 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
This article examines the scientific validity of roadside THC testing devices used in impaired driving enforcement and discusses a zero-tolerance policy framework. Roadside THC tests present significant clinical and forensic limitations, as they measure THC presence without distinguishing between recent use (potentially impairing) and residual THC from past use that does not impair cognitive or motor function. For clinicians, this distinction is critical because patients may test positive for THC days or weeks after consumption when no functional impairment exists, yet face legal consequences that could affect employment, driving privileges, and mental health. Understanding the gap between positive THC detection and actual impairment is essential for physicians counseling patients about cannabis use, driving safety, and legal risks, particularly as patients may be penalized despite not being acutely intoxicated. Clinicians should counsel cannabis-using patients that roadside testing cannot reliably measure impairment and advise caution with any driving after use, while advocating for more sophisticated testing methods that distinguish acute intoxication from past use in their communities.
“The problem with roadside THC testing isn’t just the science, though that’s certainly flawed; it’s that we’re trying to criminalize a measurable compound without any evidence that the level detected correlates with impairment, which is fundamentally different from how we approach alcohol where we have decades of pharmacokinetic data.”
🚗 Roadside THC testing presents significant challenges for clinical practice because current devices cannot reliably distinguish between recent intoxication and residual THC from past use, given the cannabinoid’s variable metabolism and prolonged detectability in blood and saliva. While zero-tolerance policies may seem straightforward from a public safety standpoint, the underlying science reveals important limitations: THC impairment does not correlate predictably with blood concentrations, individual tolerance varies considerably, and detection technology continues to evolve in accuracy and specificity. Healthcare providers should be aware that patients may face legal consequences based on roadside tests with questionable validity, which could affect clinical counseling around cannabis use and driving safety. When discussing driving risk with cannabis users, clinicians should acknowledge that while impairment is real, the current regulatory framework relies on testing methods that don’t yet reliably measure functional impairment in the way alcohol breathalyzers do. Practically,
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: